Signum Biosciences aims to develop novel G-protein coupled receptor (GPCR) modulating therapeutics to treat common skin disorders. Signum intends to use the first SBIR grant to develop anti-inflammatory
In the GFT505-209-4 and GFT505-109-6 studies, GFT505 showed insulin-sensitising effects in non-diabetic subjects. An international expert panel chaired by Bart Staels, president of the Scientific Advisory Board, encouraged
Cyprotex and TB Alliance aim to discover TB drugs that will shorten treatment, be effective against susceptible and resistant strains, be compatible with antiretroviral therapies for those HIV-TB
Lorcaserin is the subject of an exclusive licensing agreement concluded between Eisai’s US subsidiary Eisai Inc and Arena Pharmaceuticals GmbH, the wholly-owned Swiss subsidiary of Arena Pharmaceuticals Inc,
PrimeSuite 2011 is a pre-market CCHIT Certified 2011 Ambulatory EHR, additionally certified for Child Health and Cardiovascular Medicine, with optional Advanced Reporting. VHA Purchased Services and Strategic Outsourcing
Alkermes said that the FDA will consider the Advisory Committee’s recommendation in its review of the supplemental new drug application (sNDA) that the company has submitted for Vivitrol.
In his role, Ray is expected to lead business development efforts aimed at expanding the company’s pipeline of differentiated protein therapeutics. Prior to joining Itero, Ray was the
As per the terms of the license agreement, GLG Pharma has agreed to pay Moffitt when various commercialisation milestones are reached, as well as make royalty payments on
The Phase II clinical trial, coordinated by AGTC, is being conducted at The University of Massachusetts by Terrence Flotte and Cincinnati Children’s Hospital Medical Center by Bruce Trapnell.
Aricept transdermal patch NDA, if approved, is expected to be marketed by Eisai Inc, Easai’s US subsidiary, where it will co-promote the patch in collaboration with Pfizer. Easai
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.